Skip to main content

IMPLICACION DE HLA-E EN LA RESPUESTA ADAPTATIVA DE LAS CELULAS NK NKG2C+ A LA INFECCION POR EL CITOMEGALOVIRUS: ENSEÑANZAS DE LA INMUNOSUPRESION E IMPLICACIONES CLINICAS

PID2019-110609RB-C21

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake

  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Ataya, Michelle|||0000-0002-9249-1083
  • Moraitis, Ilias|||0000-0002-3879-8623
  • Campos-Ruiz, Miriam|||0000-0002-4454-4267
  • Altadill, Mireia|||0000-0002-3118-8654
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
  • Moles, Anna|||0000-0002-3915-0060
  • López-Botet, Miguel|||0000-0003-4882-065X
Epstein Barr virus (EBV) causes a highly prevalent and lifelong infection contributing to the development of some malignancies. In addition to the key role played by T cells in controlling this pathogen, NK cells mediate cytotoxicity and IFNγ production in response to EBV-infected B cells in lytic cycle, both directly and through antibody (Ab)-dependent activation. We recently described that EBV-specific Ab-dependent NK cell interaction with viral particles (VP) bound to B cells triggered degranulation and TNFα secretion but not B cell lysis nor IFNγ production. In this report we show that NK cell activation under these conditions reduced B cell transformation by EBV. NK cells eliminated VP from the surface of B cells through a specific and active process which required tyrosine kinase activation, actin polymerization and Ca2+, being independent of proteolysis and perforin. VP were displayed at the NK cell surface before being internalized and partially shuttled to early endosomes and lysosomes. VP transfer was encompassed by a trogocytosis process including the EBV receptor CD21, together with CD19 and CD20. Our study reveals a novel facet of the antibody-dependent NK cell mediated response to this viral infection. Epstein-Barr virus (EBV) is a member of the herpesvirus family which causes a frequent and lifelong infection. The immune system is unable to fully eliminate the virus, which remains dormant in infected B lymphocytes. EBV reactivation leads to the production of new infective particles, spreading to other cells and favoring its transmission. EBV infection goes generally unnoticed in healthy individuals, though it may occasionally cause a disease termed Infectious Mononucleosis, as well as severe disorders in patients with a defective immune response. Remarkably, EBV has oncogenic potential contributing to the development of some tumors, and has been associated to autoimmune diseases. T lymphocytes and Natural Killer (NK) cells play an essential role in the defense against EBV, killing infected cells when the virus reactivates. Antiviral NK cell functions may be also triggered by antibodies (Ab) recognizing infected cells. In this report we provide the first evidence supporting that NK cells in combination with anti-EBV Ab are able to eliminate the virus attached to the surface of B cells, reducing their infection without killing them.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Villafranca-Magdalena, Beatriz|||0000-0001-9921-919X
  • Viñas-Casas, Maria|||0000-0003-1438-7325
  • Gamez-Garcia, Andrés|||0000-0003-4927-3678
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Ivanova, Saska
  • Denizli, Melek|||0000-0002-9325-2535
  • Faúndez Vidiella, Claudia
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies. {'@id': 'Par2', 'graphic': {'@position': 'anchor', '@xlink:href': '41419_2023_6229_Figa_HTML', '@id': 'd32e443'}}.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Alloreactive adaptive natural killer cells in renal transplantation: potential contribution to allograft microvascular inflammation

  • Alari-Pahissa, Elisenda
  • Federico-Vega, Judith
  • Ataya Fernández, Michelle, 1993-
  • Buxeda, Anna
  • Bello-Rico, Víctor
  • Gimeno, Javier
  • Yélamos López, José
  • Altadill, Mireia
  • Sanz-Ureña, Sara
  • Riera, Marta
  • Burballa Tàrrega, Carla, 1988-
  • Chamoun, Betty Odette
  • Pérez-Sáez, María José
  • Redondo Pachón, María Dolores
  • Vilches, Carlos
  • Crespo Barrio, Marta
  • López-Botet, M. (Miguel)
Inhibitory killer cell immunoglobulin-like receptors (iKIRs) are randomly expressed by natural killer (NK) cell subsets and recognize motifs shared by HLA class-I (HLA-I) allotypes. Such interactions prevent NK cell autoreactivity while enhancing their response against cells lacking those HLA-I molecules (missing self), a situation defined in transplantation as iKIR-HLA-I mismatch (iKIR-MM), whose genotypic prediction has been associated with microvascular inflammation (MVI). Herein, we compared iKIR-MM in kidney transplant recipients with MVI ≥2 (n = 19) and controls with MVI ≤1 (n = 36). In parallel to genetic analysis of iKIR-MM, which was more frequent in MVI ≥2 patients, putative alloreactive iKIR-MM NK cells were defined by flow cytometry as NKG2A(-) cells bearing self-specific but lacking donor-specific iKIR. Although iKIR-MM NK cells were detected in both groups, their pretransplant numbers were higher in MVI ≥2 patients (median = 11.02, interquartile range = 0-58.31 vs median = 0, interquartile range = 0-9.46), especially in the presence of donor-specific antibodies or C4d, and correlated with MVI grade. Pretransplant, a subset of MVI ≥2 patients showed high proportions and numbers of oligoclonal iKIR-MM NK cells, which displayed an NKG2C(+) adaptive phenotype associated with cytomegalovirus infection. This pilot study provides a novel perspective on the contribution of iKIR-MM NK cells to MVI, with potential practical implications., J.F.V. had support from a grant awarded by the Catalan Transplantation Foundation. This study was supported by grants: “PI20/00090” and “PI23/00061”, funded by Instituto de Salud Carlos III (ISCIII) FIS and co-funded by the European Union (EU-FEDER); “PID2019-110609RB-C21” and “PID2019-110609RB-C22” (funded by Agencia Estatal de Investigación and cofunded by EU-FEDER; “P105/U/2018” (Fundació la Marató de TV3); “RD21/0005/0022” (National Network for Kidney Research RICORS2024, co-funded by Spanish Ministry of Health-ISCIIII and European Union-NextGenerationEU), Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS 2040-Renal (RD24/0004/0003) funded by European Union – NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), and a 2023 Nephrology Research grant (Spanish Society of Nephrology S.E.N).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Adaptive NK cell response to human cytomegalovirus: Facts and open issues

  • López-Botet, M. (Miguel)
  • Maria, Andrea de
  • Muntasell i Castellví, Aura, 1972-
  • Della Chiesa, Mariella
  • Vilches, Carlos
Human cytomegalovirus (HCMV) infection exerts broad effects on the immune system. These include the differentiation and persistent expansion of a mature NK cell subset which displays a characteristic phenotypic and functional profile hallmarked by expression of the HLA-E-specific CD94/NKG2C activating receptor. Based on our experience and recent advances in the field, we overview the adaptive features of the NKG2C+ NK cell response, discussing observations and open questions on: (a) the mechanisms and influence of viral and host factors; (b) the existence of other NKG2C- NK cell subsets sharing adaptive features; (c) the development and role of adaptive NKG2C+ NK cells in the response to HCMV in hematopoietic and solid organ transplant patients; (d) their relation with other viral infections, mainly HIV-1; and (e) current perspectives for their use in adoptive immunotherapy of cancer., Research is supported by: Agencia Estatal de Investigación-FEDER (PID2019–110609RB-C21-C22/AEI/10.13039/501100011033); Fundació La Marató de TV3 (201822–10); Ministero dell’Istruzione (MIUR) - FRA 219; Ministero dell’Istruzione (MIUR): FISR2020IP_02937; ISCiii/FEDER (PI19/00328; PI22/00040) and CIBERONC.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Human cytomegalovirus antigen presentation by HLA-G in infected cells

  • Altadill, Mireia
  • Álvarez, Iñaki
  • Ataya Fernández, Michelle, 1993-
  • Heredia, Gemma
  • Alari-Pahissa, Elisenda
  • Muntasell i Castellví, Aura, 1972-
  • Llano, Manuel
  • Fuchs, Jonas
  • Vilches, Carlos
  • Hengel, Hartmut
  • Halenius, Anne
  • López-Botet, M. (Miguel)
HLA-E and -G class Ib molecules were considered unrelated to viral antigen presentation. HLA-E binds nonamers from the leader sequences of other HLA-I molecules and the human cytomegalovirus (HCMV) UL40 protein, interacting with CD94/NKG2 NK cell receptors. Yet, evidence that HLA-E may present some pathogen-derived peptides to CD8+ T lymphocytes has been reported. By contrast, HLA-G binds a broad spectrum of endogenous sequences but its role in antigen presentation is unknown. An experimental approach was set up to search for HCMV antigens displayed by HLA-G in infected cells. Among the analysed peptidome, 22 sequences corresponding to 16 HCMV molecules were identified; 17 peptides were confirmed to interact in vitro with HLA-G of which 10 displayed characteristic anchor residues. As compared to the response in short-term (6 h) assays to immunodominant IE-1 and pp65 antigens, none of the HLA-G-binding peptides stimulated cytokine production by CD8+ T cells from HCMV-seropositive blood donors (n = 15). Following a 14-day peptide stimulation of PBMC and expansion with IL-2, CD8+ T cells specifically responding to a subset of these viral antigens were detected in some individuals, yet were not restricted by HLA-G in functional assays. A subset of viral peptides did bind to both HLA-G and -E but were not recognised by CD94/NKG2 NK cell receptors. Our results provide the first evidence that HLA-G may display potentially immunogenic viral peptides in HCMV-infected cells, yet do not support their ability to promote HLA-G-restricted CD8+ T cell responses nor to modulate NK cell functions., The work was supported by the Agencia Estatal de Investigación-FEDER (PID2019-110609RB-C21-C22/AEI/10.13039/501100011033) and the Deutsche Forschungsgemeinschaft: grant FOR2830, project HA 6035/2-2 (A.H.) and HE 2526/9-2 (H.H.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake

  • Alari-Pahissa, Elisenda
  • Ataya, Michelle
  • Moraitis, Ilias
  • Campos-Ruiz, Miriam
  • Altadill, Mireia
  • Muntasell, Aura
  • Moles, Anna
  • López-Botet, Miguel
Epstein Barr virus (EBV) causes a highly prevalent and lifelong infection contributing to the development of some malignancies. In addition to the key role played by T cells in controlling this pathogen, NK cells mediate cytotoxicity and IFNγ production in response to EBVinfected B cells in lytic cycle, both directly and through antibody (Ab)-dependent activation. We recently described that EBV-specific Ab-dependent NK cell interaction with viral particles (VP) bound to B cells triggered degranulation and TNFα secretion but not B cell lysis nor IFNγ production. In this report we show that NK cell activation under these conditions reduced B cell transformation by EBV. NK cells eliminated VP from the surface of B cells through a specific and active process which required tyrosine kinase activation, actin polymerization and Ca2+, being independent of proteolysis and perforin. VP were displayed at the NK cell surface before being internalized and partially shuttled to early endosomes and lysosomes. VP transfer was encompassed by a trogocytosis process including the EBV receptor CD21, together with CD19 and CD20. Our study reveals a novel facet of the antibody- dependent NK cell mediated response to this viral infection., The work was supported by grants SAF2016-80363-C2-1-R (MINECO/FEDER/UE), awarded to MLB by Ministerio de Economı´a y Competitividad and PID2019-110609RB-C21/AEI/ 10.13039/501100011033 awarded to MLB by Agencia Estatal de Investigación.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Alloreactive adaptive natural killer cells in renal transplantation: potential contribution to allograft microvascular inflammation

  • Alari-Pahissa, Elisenda
  • Federico-Vega, Judith
  • Ataya Fernández, Michelle, 1993-
  • Buxeda, Anna
  • Bello-Rico, Víctor
  • Gimeno, Javier
  • Yélamos López, José
  • Altadill, Mireia
  • Sanz-Ureña, Sara
  • Rovira Riera, Marta
  • Burballa Tàrrega, Carla, 1988-
  • Chamoun, Betty Odette
  • Pérez-Sáez, María José
  • Redondo Pachón, María Dolores
  • Vilches, Carlos
  • Crespo Barrio, Marta
  • López-Botet, M. (Miguel)
Inhibitory killer cell immunoglobulin-like receptors (iKIRs) are randomly expressed by natural killer (NK) cell subsets and recognize motifs shared by HLA class-I (HLA-I) allotypes. Such interactions prevent NK cell autoreactivity while enhancing their response against cells lacking those HLA-I molecules (missing self), a situation defined in transplantation as iKIR-HLA-I mismatch (iKIR-MM), whose genotypic prediction has been associated with microvascular inflammation (MVI). Herein, we compared iKIR-MM in kidney transplant recipients with MVI ≥2 (n = 19) and controls with MVI ≤1 (n = 36). In parallel to genetic analysis of iKIR-MM, which was more frequent in MVI ≥2 patients, putative alloreactive iKIR-MM NK cells were defined by flow cytometry as NKG2A(-) cells bearing self-specific but lacking donor-specific iKIR. Although iKIR-MM NK cells were detected in both groups, their pretransplant numbers were higher in MVI ≥2 patients (median = 11.02, interquartile range = 0-58.31 vs median = 0, interquartile range = 0-9.46), especially in the presence of donor-specific antibodies or C4d, and correlated with MVI grade. Pretransplant, a subset of MVI ≥2 patients showed high proportions and numbers of oligoclonal iKIR-MM NK cells, which displayed an NKG2C(+) adaptive phenotype associated with cytomegalovirus infection. This pilot study provides a novel perspective on the contribution of iKIR-MM NK cells to MVI, with potential practical implications., J.F.V. had support from a grant awarded by the Catalan Transplantation Foundation. This study was supported by grants: “PI20/00090” and “PI23/00061”, funded by Instituto de Salud Carlos III (ISCIII) FIS and co-funded by the European Union (EU-FEDER); “PID2019-110609RB-C21” and “PID2019-110609RB-C22” (funded by Agencia Estatal de Investigación and cofunded by EU-FEDER; “P105/U/2018” (Fundació la Marató de TV3); “RD21/0005/0022” (National Network for Kidney Research RICORS2024, co-funded by Spanish Ministry of Health-ISCIIII and European Union-NextGenerationEU), Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS 2040-Renal (RD24/0004/0003) funded by European Union – NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), and a 2023 Nephrology Research grant (Spanish Society of Nephrology S.E.N).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Adaptive NK cell response to human cytomegalovirus: Facts and open issues

  • López-Botet, M. (Miguel)
  • Maria, Andrea de
  • Muntasell i Castellví, Aura, 1972-
  • Della Chiesa, Mariella
  • Vilches, Carlos
Human cytomegalovirus (HCMV) infection exerts broad effects on the immune system. These include the differentiation and persistent expansion of a mature NK cell subset which displays a characteristic phenotypic and functional profile hallmarked by expression of the HLA-E-specific CD94/NKG2C activating receptor. Based on our experience and recent advances in the field, we overview the adaptive features of the NKG2C+ NK cell response, discussing observations and open questions on: (a) the mechanisms and influence of viral and host factors; (b) the existence of other NKG2C- NK cell subsets sharing adaptive features; (c) the development and role of adaptive NKG2C+ NK cells in the response to HCMV in hematopoietic and solid organ transplant patients; (d) their relation with other viral infections, mainly HIV-1; and (e) current perspectives for their use in adoptive immunotherapy of cancer., Research is supported by: Agencia Estatal de Investigación-FEDER (PID2019–110609RB-C21-C22/AEI/10.13039/501100011033); Fundació La Marató de TV3 (201822–10); Ministero dell’Istruzione (MIUR) - FRA 219; Ministero dell’Istruzione (MIUR): FISR2020IP_02937; ISCiii/FEDER (PI19/00328; PI22/00040) and CIBERONC.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Human cytomegalovirus antigen presentation by HLA-G in infected cells

  • Altadill, Mireia
  • Álvarez, Iñaki
  • Ataya Fernández, Michelle, 1993-
  • Heredia, Gemma
  • Alari-Pahissa, Elisenda
  • Muntasell i Castellví, Aura, 1972-
  • Llano, Manuel
  • Fuchs, Jonas
  • Vilches, Carlos
  • Hengel, Hartmut
  • Halenius, Anne
  • López-Botet, M. (Miguel)
HLA-E and -G class Ib molecules were considered unrelated to viral antigen presentation. HLA-E binds nonamers from the leader sequences of other HLA-I molecules and the human cytomegalovirus (HCMV) UL40 protein, interacting with CD94/NKG2 NK cell receptors. Yet, evidence that HLA-E may present some pathogen-derived peptides to CD8+ T lymphocytes has been reported. By contrast, HLA-G binds a broad spectrum of endogenous sequences but its role in antigen presentation is unknown. An experimental approach was set up to search for HCMV antigens displayed by HLA-G in infected cells. Among the analysed peptidome, 22 sequences corresponding to 16 HCMV molecules were identified; 17 peptides were confirmed to interact in vitro with HLA-G of which 10 displayed characteristic anchor residues. As compared to the response in short-term (6 h) assays to immunodominant IE-1 and pp65 antigens, none of the HLA-G-binding peptides stimulated cytokine production by CD8+ T cells from HCMV-seropositive blood donors (n = 15). Following a 14-day peptide stimulation of PBMC and expansion with IL-2, CD8+ T cells specifically responding to a subset of these viral antigens were detected in some individuals, yet were not restricted by HLA-G in functional assays. A subset of viral peptides did bind to both HLA-G and -E but were not recognised by CD94/NKG2 NK cell receptors. Our results provide the first evidence that HLA-G may display potentially immunogenic viral peptides in HCMV-infected cells, yet do not support their ability to promote HLA-G-restricted CD8+ T cell responses nor to modulate NK cell functions., The work was supported by the Agencia Estatal de Investigación-FEDER (PID2019-110609RB-C21-C22/AEI/10.13039/501100011033) and the Deutsche Forschungsgemeinschaft: grant FOR2830, project HA 6035/2-2 (A.H.) and HE 2526/9-2 (H.H.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.